Literature DB >> 18515793

Immeasurable time bias in observational studies of drug effects on mortality.

Samy Suissa1.   

Abstract

Observational studies suggesting that some drugs are effective at reducing mortality may have been subject to "immeasurable time bias" arising from the unidentified presence of hospitalizations when defining drug exposure with computerized health databases. The author illustrates the bias using a case-control study of 1,313 deaths and 1,313 controls selected from a cohort of 2,049 patients with chronic obstructive pulmonary disease from Saskatchewan, Canada, identified from 1990 and followed up through 1999. Different approaches were used to estimate the rate ratio of death associated with inhaled corticosteroid exposure, defined by a prescription dispensed in the 30-day period prior to the index date. More cases had been hospitalized during the 30-day exposure period (72%) than controls (26%), with lower durations of stay for cases who received an inhaled corticosteroid prescription (9.9 vs.16.2 days), thus introducing variations in measurable exposure times. The raw analysis that did not consider hospitalization found a rate ratio of 0.60 (95% confidence interval (CI): 0.50, 0.73). Alternatively, analyses accounting for variations in measurable times resulted in a rate ratio of 0.93 (95% CI: 0.76, 1.14) when weighted by measurable time, while use of the Kaplan-Meier estimator of the 30-day cumulative incidence of exposure found a rate ratio of 1.35 (95% CI: 1.14, 1.60). In conclusion, immeasurable time bias may be present in several observational database studies suggesting that certain drugs are effective at reducing mortality.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18515793     DOI: 10.1093/aje/kwn135

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  56 in total

1.  Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors.

Authors:  S M Cadarette; D H Solomon; J N Katz; A R Patrick; M A Brookhart
Journal:  Osteoporos Int       Date:  2010-06-08       Impact factor: 4.507

2.  Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendations.

Authors:  Milica Nikitovic; Daniel H Solomon; Suzanne M Cadarette
Journal:  Ther Adv Chronic Dis       Date:  2010-11-01       Impact factor: 5.091

Review 3.  Measuring and improving adherence to osteoporosis pharmacotherapy.

Authors:  Suzanne M Cadarette; Andrea M Burden
Journal:  Curr Opin Rheumatol       Date:  2010-07       Impact factor: 5.006

Review 4.  Potential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapies.

Authors:  Jie Zhang; Huifeng Yun; Nicole C Wright; Meredith Kilgore; Kenneth G Saag; Elizabeth Delzell
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

5.  Methodological shortcomings.

Authors:  Falk Hoffmann; Tania Schink
Journal:  Dtsch Arztebl Int       Date:  2014-10-03       Impact factor: 5.594

6.  An Introduction to Health Care Administrative Data.

Authors:  Suzanne M Cadarette; Lindsay Wong
Journal:  Can J Hosp Pharm       Date:  2015 May-Jun

7.  Accounting for unobservable exposure time bias when using Medicare prescription drug data.

Authors:  Elizabeth A Cook; Kathleen M Schneider; Elizabeth Chrischilles; John M Brooks
Journal:  Medicare Medicaid Res Rev       Date:  2013-11-15

8.  Statin adherence and the risk of major coronary events in patients with diabetes: a nested case-control study.

Authors:  Päivi Ruokoniemi; Maarit J Korhonen; Arja Helin-Salmivaara; Piia Lavikainen; Antti Jula; Seppo Y T Junnila; Raimo Kettunen; Risto Huupponen
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

9.  Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia.

Authors:  Charles E Leonard; Colleen M Brensinger; Christina L Aquilante; Warren B Bilker; Denise M Boudreau; Rajat Deo; James H Flory; Joshua J Gagne; Margaret J Mangaali; Sean Hennessy
Journal:  Diabetes Care       Date:  2018-02-02       Impact factor: 19.112

10.  Preadmission statin use and one-year mortality among patients in intensive care - a cohort study.

Authors:  Steffen Christensen; Reimar W Thomsen; Martin B Johansen; Lars Pedersen; Reinhold Jensen; Kim M Larsen; Anders Larsson; Else Tønnesen; Henrik Toft Sørensen
Journal:  Crit Care       Date:  2010-03-09       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.